Trusted Resource for Clinical Trials, Protocols & Progress
Rare disease clinical trials often rely on a small number of specialized sites and highly experienced principal investigators (PIs). In many cases, a single PI may serve as the only qualified clinician with in-depth knowledge of the disease, investigational product, and protocol-specific assessments at their site.
Click to read the full article.
Conditional Marketing Authorization (CMA) is a regulatory pathway in the European Union that allows for the early approval of medicines that address serious or life-threatening diseases, especially where there is an unmet medical need — including rare and orphan conditions. Administered by the European Medicines Agency (EMA), this pathway provides faster access to patients while requiring the sponsor to complete confirmatory studies post-approval.
Click to read the full article.
In rare disease research, every datapoint matters. Due to the small patient populations, heterogeneous outcomes, and complex endpoints, publishing accurate and timely trial results becomes not just a regulatory requirement but a moral imperative. Transparency in clinical trial reporting ensures that patients, caregivers, regulators, and the scientific community have access to essential data that can shape future research, guide treatment decisions, and promote trust in clinical science.
Click to read the full article.
First-in-human (FIH) trials mark the critical juncture where laboratory discoveries transition into patient care. For ultra-rare disorders—conditions affecting fewer than 1 in 50,000 people—these trials are uniquely complex. Unlike common diseases where large populations enable robust trial design, ultra-rare disorders demand innovative methodologies, regulatory flexibility, and strong collaboration with patient communities. With limited natural history data, a small number of eligible patients, and ethical sensitivities around risk exposure, FIH studies must balance urgency with patient safety.
Click to read the full article.
Rare disease clinical trials typically involve small cohorts—sometimes fewer than 20 patients—making every datapoint crucial. These studies often require complex data collection tools to capture nuanced, protocol-specific endpoints such as functional scores, genetic markers, or patient-reported outcomes (PROs).
Click to read the full article.
The Priority Review Voucher (PRV) is a regulatory incentive offered by the U.S. Food and Drug Administration (FDA) to encourage drug development for underserved populations, particularly in rare and neglected diseases. The PRV allows the sponsor to expedite FDA review of a subsequent new drug application (NDA) or biologics license application (BLA), reducing the review time from the standard 10 months to 6 months.
Click to read the full article.
Orphan drug development offers unique opportunities—and unique challenges. Rare disease studies often receive special regulatory incentives, including market exclusivity, tax credits, and fast-track designations. While these policies accelerate innovation, they can also create financial and professional conflicts of interest (COIs) for sponsors, investigators, and other stakeholders. In small patient populations, even a modestly successful trial can yield significant commercial returns, heightening the risk of undue influence on trial design, conduct, or reporting.
Click to read the full article.
Rare neurological disorders, ranging from inherited epilepsies to neurodegenerative syndromes, often present with devastating outcomes and limited treatment options. Traditional “one-size-fits-all” approaches fail to account for the genetic and molecular variability underpinning these conditions. Precision medicine, which tailors interventions based on individual genetic, molecular, and phenotypic characteristics, is revolutionizing how these disorders are managed. For patients with conditions such as Dravet syndrome, Rett syndrome, or certain leukodystrophies, precision-based strategies are opening therapeutic pathways where none previously existed.
Click to read the full article.
Rare disease clinical trials often require a multi-national approach due to the geographically dispersed nature of eligible patients. Enrolling adequate participants from a single region is rarely feasible, necessitating coordination across multiple countries, each with its own regulatory, cultural, and operational landscape.
Click to read the full article.
The U.S. Food and Drug Administration (FDA) offers Orphan Drug Designation (ODD) to sponsors developing therapies for rare diseases—conditions affecting fewer than 200,000 people in the United States. This designation provides benefits such as 7 years of market exclusivity, tax credits, fee waivers, and FDA regulatory support. However, the application process can be complex, and many sponsors—especially small biotech firms—fall into avoidable traps that delay or jeopardize designation.
Click to read the full article.
